Animal health market

The market for animal health products is estimated to be over 2 billion in the U.S, and nearly as much in Western Europe Antibiotics dominate the animal health market, and feed additives account for about 50% of that market. 

In real terms, the growth of the animal health market has been just over 1%/year since the mid-1990s. Whereas the market in the developed world is almost saturated, a rapid increase in demand is expected in developing countries. Of 1.5 billion farm animals, 1 million are located in tropical and subtropical countries. Also, more and more of the latter are raised by industrial methods and require regular medication. Likewise, an increasing number of affluent people in these countries can afford lifestyle medicines for their pets. On a global basis, an annual growth between 1.5% and 2.0% is expected in the 2006-2010 period. 

The end of patent cover for most of the modern anthelmintics means that market prices have fallen and therefore funds are lower for investment in research into animal health by pharmaceutical companies. As it is the animal health market that drives any search for anti-parasitic drugs by the pharmaceutical companies, few companies are now looking for modern anti-nematodal drugs and the market size for drugs that kill trematodes and cestodes are such that a search for new drugs cannot be financially justified. Unless a novel anthelmintic that kills nematodes happens to have activity against trematodes or cestodes, it is unlikely that new drugs will become available... 

Relatively few really new and attractive products have been introduced in the animal health market. The recently developed new and expensive human therapeutics do not play a major role in animal health. Prophylactic vaccines against the major endemic diseases are already available and are difficult to improve for a competitive price. Several other interesting vaccine candidates are stuck in the research phase due to unsurpassable difficulties to achieve sufficient efficacy. 

Human/animal biotechnology combined with the pharmaceutical/animal health market. 

In 1998, the total animal health market was worth just over 15 billion. Nutritionals, i.e. vitamins, amino-acid supplements, enzymes etc. and vaccines account for 6.3 billion worth of sales, so pharmaceutical type products, the subject of this review, comprise about 60% of the whole (Figure 1). 

In summary, there are challenges ahead for natural product drug discovery, natural products have played a major role in the Animal Health market predicting the future will be a judgement call for those involved in the industry. 

Data for AMD usage and sales in the treatment of bovine respiratory disease (BRD) have been supplied by Professor A. R. Peters. BRD is a major cause of reduced productivity and economic loss globally in the United States alone the annual total cost to the cattle industry is estimated to approach 2 billion. In 2005 the total global animal health market was estimated at 17.4 billion. Table 2.19 classifies this on the basis of product category, animal species, and country. Together AMDs and medicated feed additives constitute 27% of the total cattle, pigs, and poultry together make up 56% of the total and the United States as a country takes 36.1% of the total. In 2006 AMD... 

Lufeneron from Ciba-Geigy is the current market leader of the benzoylphenyl ureas [72]. It has been used in Europe and Japan on cotton and vegetables and markets are increasing in Latin America and South Korea. Its major application has been in the animal health market for the control of fleas on domestic dogs, cats and other animals [73-76]. It is also currently being developed as a bait for termite control [72]. 

U.S.A., in lactating dairy cattie to increase milk production. EH Lilly and Company, The Upjohn Company, and American Cyanamid Company also have interests in the commercial appHcation of recombinant bovine GH. Recombinant porcine GH [9061-23-8] preparations from several companies, eg. The Upjohn Company, Smith Kline Beecham Animal Health, Pitman-Moore, Inc., Monsanto Company, and American Cyanamid Company, are being evaluated for commercial use. Recombinant human GH for clinical use is marketed under such names as Protropin (Genentech), Umatrope (EH Lilly), Genotropin (Sumitomo), and Somatonorm (Kabi-Vitmm) by a variety of pharmaceutical companies. A listing of additional suppHers is available (2). 

The biotin market is divided between agricultural and human use, with —90% of biotin used in the animal health care market and —10% for the human nutritional market. The major producers of biotin are Hoffmann-La Roche, Lon2a, E. Merck-Darmstadt, Rhc ne-Poulenc, Sumitomo Pharmaceutical, E. Sung, and Tanabe Seiyaku (100). Worldwide production of biotin in 1994 was approximately 60 metric tons. The Hst price for pure biotin in 1995 was — 7.00/g whereas, the Hst price for technical feed-grade biotin was — 5.50/g. Biotin is used in various pharmaceutical, food, and special dietary products, including multivitamin preparations in Hquid, tablet, capsule, or powder forms. One of the commercially available products of i7-biotin is Britrit-1, which is a 1% biotin trituration used in food premixes. 

Salinomycin (180) and narasin (128) have been reported to be effective in improving feed efficiency but neither has been marketed for this use. Laidlomycin propionate (Syntex, Inc.) and tetronasin (Coopers Animal Health, Inc.) have been under investigation in cattle and sheep (181,182). 

The discovery and production of antibiotics has been of tremendous importance to human and animal health care. Prior to their discovery about half a century ago, many bacterial infections caused debilitating diseases and fatalities were high. The discovery of antibiotics was a major step in the treatment of infectious diseases, especially those caused by bacteria. Today about 50,000 tonnes of antibiotics are produced annually. About a third of this consists of penicillins, whilst tetracyclines make up about a quarter of the market. 

Bostelmann N (2000), An Examination of the Influence of Marketing Organisations on Animal Health and Meat Quality of Fattening Pigs on the Basis of Collected Slaughter Check Results, pH-values and Meat Temperatures of the Ham, Dissertation, University Berlin. 

SCA Technical Report Series, No. 34. (1996) Feral Livestock Animals - Destruction or Capture, Handling and Marketing Standing Committee on Agriculture, Animal Health Committee— Model Code of Practice for the Welfare of Animals. Canberra. 

Animal health is a segment of the life sciences industry at the interface of pharmaceuticals and agrochemicals. Global sales were 15 billion in 2005 ( 14.5 billion in 2004, 13.8 billion in 2001, inflation-adjusted). Of the top 10 companies, 9 are business units or spinoffs from pharmaceutical companies (see Table 11.9). The industry is rather concentrated, with the top 10 companies accounting for 75% of total sales. As they do in pharma, US companies dominate in animal health products. Many of the veterinary products in the portfolios had originally been developed for human use or as pesticides. In the pet (respectively companion animal) segment, which comprises cats, dogs, birds, some rodents, reptiles, and horses and represents about 40% of the total market, the association with human health is particularly prominent. 

EMEA. EMEA s mission is to contribute to the protection and promotion of public and animal health by providing high-quality evaluation of medicinal products. Its goal is to develop a single European marketing authorization controlling the safety of medicines for humans and animals. 

---